PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study
Although PPP2R1A mutations are linked to aggressive clinicopathological features, they do not independently predict endometrial carcinoma survival. Given the absence of non-hormonal targets in half of PPP2R1A-mutated carcinomas, PP2A-targeted therapies are needed. Survival analysis suggests that the role of p53 in progression likely extends beyond its interaction with PP2A.
Authors
- Masuma Khatun (ORCID: https://orcid.org/0000-0003-2976-2319)
- Ralf Bützow (ORCID: https://orcid.org/0000-0003-4366-5099)
- Taru Tuomi (ORCID: https://orcid.org/0000-0002-8900-1370)
- Anna Kanerva (ORCID: https://orcid.org/0000-0003-3355-7393)
- Riitta Koivisto-Korander (ORCID: https://orcid.org/0000-0003-4457-9002)
- Mikko Loukovaara (ORCID: https://orcid.org/0000-0002-4372-2367)
- Annukka Pasanen (ORCID: https://orcid.org/0000-0002-0079-9807)
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
Publication Details
- Journal
- International Journal of Gynecological Cancer
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1016/j.ijgc.2025.101934
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17
Funders
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- Suomen Kulttuurirahasto
- Paulon Säätiö
- K. Albin Johanssons Stiftelse
- Syöpäsäätiö